-
Je něco špatně v tomto záznamu ?
Profylaxe žilní tromboembolie po úrazu
[Postinjury thromboprophylaxis]
Cino Bendinelli, Zsolt Balogh
Jazyk čeština Země Česko
- MeSH
- antikoagulancia terapeutické užití MeSH
- časové faktory MeSH
- enoxaparin terapeutické užití MeSH
- faktor Xa MeSH
- incidence MeSH
- inhibitory faktoru Xa MeSH
- kritický stav MeSH
- lidé MeSH
- plicní embolie epidemiologie etiologie prevence a kontrola MeSH
- polysacharidy terapeutické užití MeSH
- rány a poranění komplikace MeSH
- rizikové faktory MeSH
- žilní trombóza epidemiologie etiologie prevence a kontrola MeSH
- Check Tag
- lidé MeSH
In trauma patients, pulmonary embolism occurs in up to 4% of cases and carries a mortality of 20-50%. The incidence of deep vein thrombosis (DVT) varies from 5 to 63% depending on patients' risk factors, modality of prophylaxis, and methods of detection. For these reasons, trauma patients require adequate DVT prophylaxis. RECENT FINDINGS: Spinal fracture or cord injury patients are at particular risk. Increasing injury severity, head injury, older age, lower limb injuries, and obesity are other risk factors. The current standard of care for DVT prophylaxis is enoxaparin (a low molecular weight heparin) as long as anticoagulation is not contraindicated. Unfractionated heparin alone does not provide sufficient protection against DVT. Selective factor Xa inhibitors such as fondaparinux are showing promising results. Other strategies for pulmonary embolism prevention include: graduated compression stockings, sequential compression devices, continuous passive motion, and prophylactic inferior vena cava filter. There is lack of consensus regarding the optimal DVT prophylaxis in trauma patients and few level I recommendations exist. SUMMARY: Best practice in thromboprophylaxis for trauma patients will remain on the basis of recommendations until definitive risk-benefit ratios are determined to justify the use of various mechanical and pharmacological measures, in combination or alone.
Postinjury thromboprophylaxis
Lit.: 49
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07528003
- 003
- CZ-PrNML
- 005
- 20111210144155.0
- 008
- 090901s2009 xr e cze||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a cze $b eng
- 044 __
- $a xr
- 100 1_
- $a Bendinelli, Cino
- 245 10
- $a Profylaxe žilní tromboembolie po úrazu / $c Cino Bendinelli, Zsolt Balogh
- 246 11
- $a Postinjury thromboprophylaxis
- 314 __
- $a Department of Traumatology, Division of Surgery, John Hunter Hospital, University of Newcastle, Newcastle Cino.Bendinelli@hnehealth.nsw.gov.au
- 504 __
- $a Lit.: 49
- 520 9_
- $a In trauma patients, pulmonary embolism occurs in up to 4% of cases and carries a mortality of 20-50%. The incidence of deep vein thrombosis (DVT) varies from 5 to 63% depending on patients' risk factors, modality of prophylaxis, and methods of detection. For these reasons, trauma patients require adequate DVT prophylaxis. RECENT FINDINGS: Spinal fracture or cord injury patients are at particular risk. Increasing injury severity, head injury, older age, lower limb injuries, and obesity are other risk factors. The current standard of care for DVT prophylaxis is enoxaparin (a low molecular weight heparin) as long as anticoagulation is not contraindicated. Unfractionated heparin alone does not provide sufficient protection against DVT. Selective factor Xa inhibitors such as fondaparinux are showing promising results. Other strategies for pulmonary embolism prevention include: graduated compression stockings, sequential compression devices, continuous passive motion, and prophylactic inferior vena cava filter. There is lack of consensus regarding the optimal DVT prophylaxis in trauma patients and few level I recommendations exist. SUMMARY: Best practice in thromboprophylaxis for trauma patients will remain on the basis of recommendations until definitive risk-benefit ratios are determined to justify the use of various mechanical and pharmacological measures, in combination or alone.
- 650 _2
- $a antikoagulancia $x terapeutické užití $7 D000925
- 650 _2
- $a kritický stav $7 D016638
- 650 _2
- $a enoxaparin $x terapeutické užití $7 D017984
- 650 _2
- $a faktor Xa $7 D015951
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a polysacharidy $x terapeutické užití $7 D011134
- 650 _2
- $a plicní embolie $x epidemiologie $x etiologie $x prevence a kontrola $7 D011655
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a žilní trombóza $x epidemiologie $x etiologie $x prevence a kontrola $7 D020246
- 650 _2
- $a rány a poranění $x komplikace $7 D014947
- 650 _2
- $a inhibitory faktoru Xa $7 D065427
- 700 1_
- $a Balogh, Zsolt
- 773 0_
- $w MED00156011 $t Current opinion in critical care $g Roč. 3, č. 1 (2009), s. 1-6 $x 1802-3819
- 910 __
- $a ABA008 $b B 2484 $c 422 $y 8
- 990 __
- $a 20090831155747 $b ABA008
- 991 __
- $a 20090901095503 $b ABA008
- 999 __
- $a ok $b bmc $g 673543 $s 532808
- BAS __
- $a 3
- BMC __
- $a 2009 $b 3 $c 1 $d 1-6 $i 1802-3819 $m Current Opinion in Critical Care (České vyd.) $x MED00156011
- LZP __
- $a 2009-30/mkme